Angiomyolipoma (AML) — a benign mesenchymal neoplasm composed of varying proportions of dysmorphic blood vessels, smooth muscle, and mature adipose tissue, classified by the World Health Organization as a member of the perivascular epithelioid cell tumor (PEComa) family alongside clear cell sugar tumor of the lung, lymphangiomyomatosis, and clear cell myomelanocytic tumor, arising most commonly in the kidney (approximately 80% of cases) but also documented in the liver (comprising the most common primary hepatic mesenchymal neoplasm), retroperitoneum, adrenal gland, and, rarely, the ovary and uterus — occurs in two clinically distinct populations: the sporadic form (approximately 80% of cases) affecting predominantly middle-aged women (female-to-male ratio approximately 4:1, mean age of diagnosis 45–55 years) as solitary unilateral renal masses without systemic disease, and the tuberous sclerosis complex (TSC)-associated form (approximately 20% of cases) presenting as bilateral, multiple, and frequently larger angiomyolipomas in patients carrying germline mutations in TSC1 (hamartin) or TSC2 (tuberin) that lead to constitutive mTORC1 activation, the molecular mechanism shared with lymphangiomyomatosis and the therapeutic target for mTOR inhibitor therapy; AML pathogenesis involves bi-allelic inactivation of TSC1 or TSC2 resulting in mTORC1 hyperactivation that drives the neoplastic proliferation of HMB-45-positive perivascular epithelioid cells alongside smooth muscle and adipose differentiation, and somatic TSC1/TSC2 mutations or loss of heterozygosity are detectable in a proportion of sporadic AML cases confirming a shared molecular mechanism with TSC-associated AML. AML presents most commonly as an incidental renal mass detected on CT or ultrasound performed for unrelated indications, with macroscopic fat content (CT attenuation below −10 to −20 HU within the renal mass) representing the imaging hallmark that distinguishes classical AML from renal cell carcinoma without requiring biopsy in the appropriate clinical context; approximately 5% of AML are fat-poor (fp-AML) due to minimal macroscopic fat and present as enhancing solid renal masses indistinguishable from papillary or clear cell renal cell carcinoma on CT, requiring MRI with in-phase/out-of-phase sequences, diffusion-weighted imaging, or percutaneous biopsy with immunohistochemistry (HMB-45, Melan-A, SMA, TFE3 for the epithelioid variant) for definitive diagnosis. The most feared complication of renal AML is spontaneous retroperitoneal hemorrhage (Wunderlich syndrome) — occurring most commonly in AML larger than 4 cm (the size threshold used in clinical decision-making for prophylactic intervention) or in TSC-associated AML with aneurysmal vasculature — presenting as acute flank pain, retroperitoneal hematoma, and hemodynamic instability requiring emergency angioembolization or surgical management; elective management of AML larger than 4 cm, symptomatic AML, or rapidly growing AML includes selective angioembolization (transcatheter arterial embolization with Onyx, N-butyl cyanoacrylate, or coils targeting the aneurysmal feeding vessel component) and nephron-sparing surgery (partial nephrectomy) as the preferred interventions, while mTOR inhibitor therapy (everolimus, sirolimus) achieving tumor volume reduction of 30–50% has become the standard of care for TSC-associated AML where bilateral disease and multiple lesions make surgical management impractical and angioembolization repeated across multiple bilateral lesions undesirable. Multidisciplinary AML management integrates urology (surgical and endovascular AML management, nephron-sparing surgery, emergency hemorrhage control), interventional radiology (selective angioembolization for hemorrhage or prophylactic AML reduction), nephrology (renal function preservation in TSC patients with bilateral AML requiring serial mTOR inhibitor therapy), neurology (TSC neurological manifestations management including cortical tubers, subependymal giant cell astrocytomas, and epilepsy), pulmonology (lymphangiomyomatosis monitoring in female TSC patients), genetics (TSC1/TSC2 germline mutation confirmation and family counseling), and the TSC multidisciplinary clinic that coordinates the multi-organ surveillance protocol recommended by the International TSC Consensus Guidelines — coordinated within academic centers where TSC's complexity and AML's potential for bilateral disease require concentrated multidisciplinary expertise.
AML technology platforms — whether supporting urology programs coordinating nephron-sparing surgery and angioembolization for large sporadic AML (managing preoperative CT abdomen with three-dimensional reconstruction for surgical planning, MRI for fat characterization and hemorrhage evaluation, Doppler ultrasound for surveillance of smaller lesions, emergency angiogram with embolization for hemorrhagic AML, partial nephrectomy operative documentation, and renal function monitoring post-embolization or post-surgery), interventional radiology platforms managing selective angioembolization procedures (pre-procedural CT angiography for feeding vessel mapping, intraoperative fluoroscopy and DSA records, embolization material documentation, post-procedural CT for embolization success verification), TSC multidisciplinary clinic platforms managing the multi-organ surveillance protocol (renal AML annual MRI, SGCA surveillance brain MRI, chest CT for LAM in female TSC patients, ophthalmology for retinal hamartomas, cardiac echo for rhabdomyomas in pediatric TSC, dermatology for skin hamartomas, neurology for cortical tuber epilepsy management, developmental pediatrics for neurocognitive assessment), mTOR inhibitor therapy platforms managing everolimus or sirolimus prescribing for TSC-associated AML (drug dispensing records, dose modification for stomatitis and pulmonary toxicity, renal function and lipid monitoring, drug interaction management), genetics platforms managing TSC1/TSC2 germline mutation testing and family cascade screening, and radiology platforms managing the serial imaging surveillance for sporadic AML and AML in pregnancy (where AML growth during pregnancy increases hemorrhage risk requiring adjusted surveillance intervals) — must maintain the availability and performance standards that AML's hemorrhage risk, surgical planning complexity, and TSC multi-organ surveillance demands require. This guide explains why AML tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the interventional, surgical, genetic, and long-term surveillance complexity of modern AML management.
Why AML Tech Platforms Require Specialized Monitoring Attention
AML management is defined by the life-threatening hemorrhage risk of large and aneurysmal AML (Wunderlich syndrome requiring emergency angioembolization), the interventional radiology complexity of selective angioembolization for hemorrhage control or prophylactic reduction, the surgical planning requirements of nephron-sparing partial nephrectomy for AML where negative imaging diagnosis is uncertain or fat-poor AML mimics RCC, the multi-organ surveillance complexity of TSC-associated bilateral AML managed with mTOR inhibitors alongside neurological, pulmonary, and dermatologic TSC manifestations, and the genetic counseling obligations for TSC patients and their families. Technology failures in these domains create disruptions calibrated to the hemorrhagic, surgical, pharmacologic, and surveillance consequences of AML's clinical spectrum.
Emergency angioembolization platforms have critical impact during hemorrhagic AML. Spontaneous retroperitoneal hemorrhage from ruptured angiomyolipoma — where emergency angiography with selective embolization targeting the feeding artery to the aneurysmal AML component is performed under hemodynamic monitoring in an interventional radiology suite — depends on platforms managing emergency CT angiography interpretation, DSA records, embolization material documentation, hemodynamic monitoring, and radiology information system access for prior imaging comparison. Monitor emergency angioembolization platforms at 1-minute intervals, 24/7.
Selective angioembolization planning platforms determine prophylactic AML control. Elective angioembolization for AML larger than 4 cm — where preoperative CT angiography for feeding vessel mapping determines embolization approach, where fluoroscopy-guided selective catheterization of the renal artery branch supplying the AML requires real-time imaging guidance, and where post-procedural CT verification confirms embolization completeness and absence of non-target embolization — requires continuous platform availability during procedural sessions. Monitor interventional radiology platforms at 1-minute intervals during procedural hours.
Nephron-sparing surgery platforms support partial nephrectomy planning. Partial nephrectomy for large, symptomatic, or diagnostically uncertain AML — where CT angiography guides surgical approach, where intraoperative ultrasound confirms AML resection margins, and where operative documentation records warm ischemia time and renal reconstruction — requires platforms managing preoperative three-dimensional reconstruction, operative records, and post-procedural renal function monitoring. Monitor surgical planning platforms at 1-minute intervals during operative sessions.
TSC multidisciplinary surveillance platforms coordinate multi-organ monitoring. TSC-associated AML management requires annual renal AML MRI alongside brain MRI for SGCA monitoring, chest CT for LAM in female patients, ophthalmology for retinal hamartomas, cardiac echo for rhabdomyomas in children, dermatology records, neurology for cortical tuber epilepsy, and mTOR inhibitor dose management — all coordinated through TSC multidisciplinary clinic platforms that must be reliably available at every annual review cycle and between-visit urgent consultation. Monitor TSC surveillance platforms at 1-minute intervals during clinic hours.
mTOR inhibitor therapy platforms manage everolimus and sirolimus for TSC-AML. Everolimus (10 mg daily) or sirolimus therapy for TSC-associated AML requires platforms managing drug prescribing and dispensing, dose modification for stomatitis, pneumonitis, and metabolic toxicity, renal function and lipid monitoring, drug level measurement for sirolimus, drug interaction screening (strong CYP3A4 inhibitors and inducers), and tumor response assessment MRI — where platform failures interrupt the medication management workflow of a patient who may be receiving mTOR inhibitor therapy for bilateral AML and simultaneously for SGCA, creating compounded therapy risk if monitoring platforms are unavailable. Monitor mTOR therapy platforms at 1-minute intervals during clinical hours.
What to Monitor on an AML Tech Platform
Emergency Angioembolization and Hemorrhage Management
Monitor emergency CT angiography acquisition and interpretation records, DSA fluoroscopy and roadmap imaging during selective AML embolization procedures, embolization material (Onyx, NBCA, coils) documentation and catalog access, hemodynamic monitoring records during hemorrhagic AML management, post-embolization CT verification records, blood bank and transfusion records for hemorrhagic Wunderlich syndrome, and interventional radiology on-call communication platforms at 1-minute intervals, 24/7. Alert immediately — emergency platform failures during hemorrhagic AML angioembolization eliminate the interventional radiology team's access to prior imaging comparison, hemodynamic monitoring integration, and embolization documentation at the precise moment when selective arterial occlusion decisions are being made in a hemodynamically unstable patient.
Elective Angioembolization Planning and Delivery
Monitor preoperative CT angiography for feeding vessel mapping, fluoroscopy-guided catheterization records and DSA documentation, selective embolization material deployment records, post-procedural CT verification, renal arterial anatomy documentation (polar artery identification, segment artery mapping), non-target embolization complication monitoring records, and planned follow-up imaging scheduling at 1-minute intervals during procedural sessions. Alert immediately — elective angioembolization platform failures during active procedures disrupt fluoroscopy access and embolization documentation in patients undergoing prophylactic AML reduction where selective catheterization mapping determines whether adjacent normal renal parenchyma is preserved.
Nephron-Sparing Surgery for AML
Monitor preoperative CT/MRI planning records for partial nephrectomy approach selection, intraoperative ultrasound documentation, operative records including warm ischemia time and vascular control technique, anesthesia records, postoperative renal function monitoring (creatinine, GFR), urology clinic follow-up scheduling, and pathology records confirming AML histology with HMB-45 and Melan-A immunohistochemistry at 1-minute intervals during operative and postoperative inpatient periods. Alert immediately — operative platform failures during partial nephrectomy eliminate operative documentation access at the moment when warm ischemia time and reconstruction decisions determine post-nephrectomy renal function.
Radiologic Surveillance for Sporadic AML
Monitor surveillance Doppler ultrasound scheduling and report integration for small AML (<4 cm) managed conservatively, annual CT or MRI surveillance scheduling for AML approaching 4 cm, growth rate calculation records comparing sequential imaging measurements, hemorrhage risk stratification documentation (aneurysmal vasculature identification on CT angiography), urgent imaging referral triggered by growth exceeding 0.5 cm/year or AML reaching 4 cm threshold, and incidental AML detection report routing during business hours. Alert on sustained failures — surveillance delays risk undetected growth to hemorrhage-risk size threshold in patients with sporadic AML where the 4 cm threshold determines the timing of prophylactic intervention.
TSC Multidisciplinary Surveillance Coordination
Monitor TSC multidisciplinary clinic scheduling and coordination records, annual renal AML MRI reports and volume measurement documentation, brain MRI for subependymal giant cell astrocytoma (SGCA) surveillance and measurement, chest CT for lymphangiomyomatosis (LAM) monitoring in female TSC patients, pulmonary function testing records for LAM, ophthalmology records for retinal hamartoma surveillance, cardiac echocardiogram records for pediatric cardiac rhabdomyoma monitoring, dermatology records for skin hamartoma documentation (facial angiofibromas, shagreen patches, hypomelanotic macules), neurology records for cortical tuber epilepsy management and seizure frequency, and developmental pediatrics records for neurocognitive assessment during clinic hours. Alert on sustained failures — TSC surveillance platform failures interrupt the coordinated multi-organ monitoring workflow for a patient whose AML, SGCA, LAM, and neurological manifestations require simultaneous surveillance with platform-dependent scheduling and result integration.
mTOR Inhibitor Therapy Management
Monitor everolimus and sirolimus prescribing and pharmacy dispensing records, drug level monitoring for sirolimus, complete metabolic panel and lipid panel monitoring for metabolic toxicity (hyperglycemia, hyperlipidemia), stomatitis and pulmonary toxicity documentation and dose modification records, drug interaction screening for CYP3A4 inhibitors and inducers, tumor response assessment MRI scheduling and volume measurement comparison, pediatric mTOR inhibitor dosing calculations and weight-based adjustments, and patient medication adherence portal during clinical hours. Alert immediately — mTOR inhibitor therapy platform failures interrupt the medication management, toxicity monitoring, and dose adjustment workflow of patients receiving everolimus or sirolimus for TSC-associated AML where dose interruption or missed toxicity monitoring increases adverse event risk.
Genetics and Family Cascade Screening
Monitor TSC1 and TSC2 germline mutation sequencing records, variant classification documentation, family cascade screening coordination (scheduling and results for at-risk relatives), genetic counseling session documentation, prenatal genetic counseling records for TSC patients, and clinical genetics interdisciplinary conference documentation at 1-minute intervals during clinical hours. Alert immediately — genetics platform failures during genetic counseling sessions or family cascade screening workflows interrupt the TSC mutation documentation and family risk counseling that determine which relatives require TSC surveillance initiation.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. AML programs — particularly TSC-associated AML — coordinate across urology, interventional radiology, nephrology, neurology, pulmonology, ophthalmology, dermatology, genetics, and developmental pediatrics, with emergency angioembolization access required 24/7 for hemorrhagic AML presentation. Authentication failures simultaneously block every member of the multidisciplinary team managing a patient whose surgical, interventional, pharmacologic, genetic, and multi-organ surveillance care all require continuous, coordinated platform access.
SSL Certificates
Monitor SSL certificate expiry across all patient portals, interventional radiology platforms, TSC surveillance coordination systems, mTOR inhibitor pharmacy platforms, genetics portals, and surveillance imaging portals. Certificate errors disrupt the emergency angioembolization, TSC surveillance coordination, and mTOR therapy management workflows of AML care.
HIPAA and Oncology Data Privacy Considerations
AML technology platforms handle sensitive PHI including TSC1/TSC2 germline mutation documentation with hereditary disease implications for family members, TSC multi-organ surveillance records spanning SGCA, LAM, epilepsy, and dermatologic manifestations, mTOR inhibitor prescribing and toxicity records, emergency angioembolization operative records for hemorrhagic AML, partial nephrectomy records with renal function outcome data, AML growth surveillance imaging across long-term follow-up, pediatric neurocognitive assessment records, and reproductive counseling documentation for TSC patients considering pregnancy. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components managing this PHI.
For platforms managing TSC germline mutation records alongside multi-organ surveillance documentation — where TSC1/TSC2 pathogenic variant records document a hereditary condition affecting multiple organ systems with family-member implications including predictive genetic testing for children and at-risk siblings — privacy and availability standards must reflect the sensitivity of combined oncologic, neurologic, pulmonary, reproductive, and genetic PHI managed across a patient's lifetime. Availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance for TSC programs managing AML's intersection of interventional radiology, surgical oncology, chronic pharmacotherapy, and multi-system surveillance PHI.
Alerting Strategy for AML Tech Platforms
Immediate 24/7 alerting for emergency platforms: Emergency angioembolization CT angiography, DSA fluoroscopy, hemodynamic monitoring, and blood bank platforms for hemorrhagic AML management. These must be available at any hour — Wunderlich syndrome is an emergency that does not respect business hours.
Immediate alerting during procedural sessions: Elective angioembolization fluoroscopy, DSA, and embolization documentation platforms during active prophylactic AML embolization procedures.
Immediate alerting during operative sessions: Nephron-sparing surgery planning, intraoperative ultrasound, and operative documentation platforms during active partial nephrectomy.
Immediate business-hours alert: mTOR inhibitor therapy management, TSC multidisciplinary clinic coordination, genetics consultation, and toxicity monitoring platforms. Alert the moment these fail during active clinical encounters.
Sustained-failure alert (10–15 minutes): Sporadic AML surveillance imaging scheduling, growth rate tracking, TSC multi-organ surveillance coordination between clinic visits, and AML tumor registry documentation platforms.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms AML platform availability from geographies where specialized TSC multidisciplinary clinics and high-volume interventional radiology programs concentrate — important for platforms supporting TSC patients whose bilateral AML, SGCA, LAM, and neurological manifestations require coordinated expert management not available at regional hospitals.
Status Page for AML Care Team Communication
A real-time status page gives urologic surgeons planning partial nephrectomy for AML, interventional radiologists performing elective or emergency angioembolization, nephrologists managing renal function in bilateral TSC-associated AML, neurologists coordinating SGCA and epilepsy management, pulmonologists monitoring LAM in female TSC patients, geneticists issuing TSC1/TSC2 germline mutation reports, and mTOR inhibitor-prescribing oncologists immediate platform visibility without requiring inbound IT support contact. During an emergency angioembolization platform outage when a patient with ruptured angiomyolipoma presenting with Wunderlich syndrome requires emergency DSA and embolization while the interventional radiology team cannot access prior renal CT angiography for AML feeding vessel anatomy, a status page enables immediate contingency protocol activation including alternative imaging access pathways and paper-based procedure documentation.
Include the status page URL in emergency angioembolization downtime procedures, TSC multidisciplinary clinic fallback workflows, mTOR inhibitor pharmacy emergency access protocols, and nephron-sparing surgery planning contingency procedures.
Vigilmon Setup for AML Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Emergency angioembolization / CT angiography / DSA (24/7) | 1 min | Slack + PagerDuty (24/7) | | Elective angioembolization / fluoroscopy / embolization records (procedural hours) | 1 min | Slack + PagerDuty (procedural hours) | | Nephron-sparing surgery planning / intraoperative ultrasound | 1 min | Slack + PagerDuty (surgical hours) | | mTOR inhibitor therapy management (everolimus / sirolimus) | 1 min | Slack + PagerDuty (business hours) | | TSC multidisciplinary surveillance coordination | 1 min | Slack + PagerDuty (clinic hours) | | Genetics / TSC1-TSC2 mutation testing / family cascade screening | 1 min | Slack + PagerDuty (business hours) | | Sporadic AML surveillance imaging scheduling | 2 min | Slack (business hours) | | TSC multi-organ surveillance (brain MRI / chest CT / ophthalmology) | 2 min | Slack (business hours) | | mTOR toxicity monitoring (metabolic panel / lipids) | 2 min | Slack (business hours) | | Patient communication portal | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure emergency angioembolization CT angiography and DSA platforms with 24/7 immediate alerting
- Add elective angioembolization fluoroscopy and embolization documentation platforms with immediate alerting during procedural hours
- Configure nephron-sparing surgery planning and intraoperative ultrasound with immediate alerting during operative sessions
- Add mTOR inhibitor therapy management and toxicity monitoring with immediate business-hours alerting
- Configure TSC multidisciplinary surveillance coordination with immediate clinic-hours alerting
- Add genetics and TSC1/TSC2 mutation testing platforms with immediate business-hours alerting
- Configure sporadic AML surveillance imaging scheduling with sustained-failure alerting
- Add TSC multi-organ surveillance (brain MRI, chest CT, ophthalmology, neurology) with sustained-failure alerting
- Configure mTOR toxicity monitoring metabolic and lipid panels with sustained-failure alerting
- Enable SSL certificate monitoring across all clinical, interventional radiology, pharmacy, genetics, and surveillance domains
- Add the status page URL to emergency angioembolization downtime procedures, TSC multidisciplinary clinic fallback workflows, and mTOR inhibitor pharmacy emergency access protocols
Conclusion
AML technology platforms are embedded in clinical decisions where emergency angioembolization platform availability during a hemorrhagic Wunderlich syndrome presentation — where the interventional radiologist performing emergency DSA-guided selective embolization of a ruptured 7 cm right renal AML in a hemodynamically unstable 38-year-old woman with TSC2 germline mutation requires simultaneous access to prior CT angiography for feeding artery anatomy, DSA fluoroscopy for real-time arterial roadmap guidance, embolization material catalog for Onyx volume selection, hemodynamic monitoring integration, blood bank records for ongoing transfusion support, and the prior renal MRI to identify the contralateral left kidney's AML burden before deciding on embolization aggressiveness — cannot be interrupted by platform outage at the precise moment when selective versus super-selective embolization technique determination, embolization material volume calculation, and non-target embolization avoidance decisions require real-time platform access for a patient in whom aggressive embolization that unnecessarily sacrifices normal renal parenchyma in the setting of bilateral AML and compromised bilateral renal reserve would create post-embolization renal insufficiency requiring dialysis; where mTOR inhibitor therapy platform availability during an everolimus dose escalation visit for a 31-year-old man with TSC2 germline mutation whose bilateral renal AML have grown from a combined volume of 180 mL to 310 mL over 18 months of initial observation — where the nephrology-oncology team requires platform access to prior MRI volume measurements for growth rate calculation, creatinine and GFR trend to assess renal function reserve before initiating everolimus, baseline lipid panel for mTOR inhibitor metabolic risk stratification, current medication list for CYP3A4 interaction screening, and the SGCA brain MRI to determine whether simultaneous SGCA treatment indication for everolimus exists — cannot be delayed by platform unavailability when the clinical decision to initiate mTOR inhibitor therapy versus pursue angioembolization first requires integrated access to the entire multi-organ TSC surveillance record; and where annual TSC surveillance platform availability during the multidisciplinary clinic visit of a 16-year-old girl with TSC1 germline mutation — where the neurology team reviewing MRI for cortical tuber burden and seizure control, the nephrology team measuring bilateral AML volumes on renal MRI for everolimus dose adequacy assessment, the pulmonology team reviewing chest CT for early LAM changes, the genetics team updating family cascade screening status for newly identified at-risk siblings, and the developmental pediatrics team completing neurocognitive assessment and school accommodation planning must all simultaneously access and coordinate through the same TSC platform — determines whether this adolescent patient's multi-system TSC management achieves the coordinated surveillance and treatment optimization that minimizes her lifetime risk of AML hemorrhage, SGCA hydrocephalus, LAM respiratory failure, and epilepsy-related morbidity. A DSA fluoroscopy platform that fails when an interventional radiologist is selectively catheterizing the feeding artery to a ruptured 9 cm AML in a hemodynamically compromised TSC patient, an mTOR inhibitor pharmacy platform inaccessible when a nephrologist must approve everolimus dispensing for a patient whose renal AML just exceeded bilateral intervention threshold, a TSC multidisciplinary surveillance platform unavailable when a tumor board must simultaneously review renal MRI, brain MRI, and pulmonary function data to determine whether to escalate everolimus dosing or add embolization — these are not IT incidents. They are clinical disruptions in the management of a condition whose hemorrhage risk requires 24/7 emergency platform readiness and whose TSC-associated multi-organ complexity requires integrated surveillance platform availability across nephrology, neurology, pulmonology, genetics, and interventional radiology.
Uptime monitoring gives AML tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to urology programs, interventional radiology departments, TSC clinics, genetics services, and compliance auditors that platform operational reliability matches the emergency hemorrhage, surgical, pharmacologic, genetic, and multi-organ surveillance demands of modern AML care.
Start monitoring your AML care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #AML #angiomyolipoma #TSC #tuberoussclerosisscomplex #PEComa #mTOR #everolimus #sirolimus #angioembolization #partinephrectomy #Wunderlichtyndrome #renalmass #LAM #lymphangiomyomatosis #SGCA #genetics #HIPAA #cancertech #healthtech #digitalhealth #uptime #sre